Neoadjuvant Nivolumab Plus Electroporation With Curative Intent Safe and Possible in HCC
October 6th 2020Neoadjuvant immunotherapy with nivolumab plus percutaneous electroporation has demonstrated early signals of promise in the treatment of patients with Barcelona Clinic Liver Cancer class A hepatocellular carcinoma, according to preliminary reports from the phase 2 NIVOLEP trial.
Read More
ILCA Data Reignite Interest in AFP as a Biomarker for HCC
October 4th 2020Although the use of α-fetoprotein has long been established in hepatocellular carcinoma as a biomarker for screening and diagnosis, its role in treatment selection and prognosis following systemic therapy is a moving target.
Read More
SIRT Administered With Nivolumab Demonstrates Positive Safety, Tolerability Results in HCC
October 3rd 2020Findings from the NASIR-HCC phase 2 clinical trial demonstrated the safety and tolerability of nivolumab administered with selective internal radiation therapy containing yttrium-90 resin in patients who were ineligible for transarterial chemoembolization.
Read More
Exploring Immunotherapy Combinations for the Treatment of HCC
September 18th 2018Novel immunotherapy combinations are currently under investigation for the treatment of patients with hepatocellular carcinoma, with several promising phase III trials incorporating checkpoint inhibitors now underway. Finding successful ways to combine these therapies is among the most significant trends emerging as part of the next wave of discovery in the field, according to experts.
Read More
Cabozantinib Improves Survival in Previously Treated Patients With HBV+ HCC
September 15th 2018Second-line therapy with cabozantinib demonstrated efficacy in treating patients with hepatocellular carcinoma who also had a history of hepatitis B virus infection, according to findings from a subgroup analysis of the phase III CELESTIAL trial.
Read More
Recent Advancements for the Treatment of Liver Cancer
September 15th 2018Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the current treatment landscape for liver cancer and the advances seen over the last decade at the 2018 International Liver Cancer Association Annual Conference.
Watch
Deep, Durable Responses Seen With Atezolizumab Combo For Frontline HCC Treatment
September 15th 2018Strong efficacy signals and a tolerable safety profile were observed with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma, according to preliminary findings presented at the 2018 International Liver Cancer Association Annual Conference.
Read More
Sequencing Strategies Necessary After Expansion of Therapy Options in HCC
September 15th 2018According to a presentation during the 2018 International Liver Cancer Association Annual Conference, the rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded systemic treatment options over the last 2 years. This has created a need for new sequencing strategies in HCC.
Read More
Expert Stresses Importance of Cultivating Tailored Treatment in HCC
September 14th 2018Fabio Piscaglia, MD, discusses the updated 2018 European Association for the Study of the Liver clinical guidelines, which were presented during the 12th International Liver Cancer Association Annual Conference in London, United Kingdom.
Read More
Targeted Oncology Partners With The International Liver Cancer Association
July 17th 2018<em>Targeted Oncology</em>, a print and digital resource that offers content and expert opinions on precision medicine in oncology, becomes partners with the International Liver Cancer Association, announced Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of <em>Targeted Oncology.</em>
Read More
Finn Shares Insight on Practice-Changing Studies in Liver Cancer
September 20th 2017Multidisciplinary findings across the field of hepatocellular carcinoma will be showcased at the 11th International Liver Cancer Association Annual Conference on September 15 to 17 in Seoul, South Korea. Abstracts already under discussion at this year’s ILCA conference include pivotal research on VGEF inhibitors, immunotherapy regimens, and biomarkers.
Read More
Predictive Biomarkers Not Found in STORM Study for Sorafenib in HCC
September 18th 2017Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib. According to an analysis of the phase III STORM study presented at the 11th International Liver Cancer Association Annual Conference, a predictive biomarker for recurrence was not uncovered.
Read More
Lenvatinib Continues to be Noninferior to Sorafenib in HCC, Updated Results Show
September 17th 2017According to updated phase III results presented at the 11th Annual International Liver Cancer Association Conference, first-line therapy with Lenvatinib in the frontline setting continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate versus sorafenib for patients with unresectable hepatocellular carcinoma
Read More
Direct Acting Antivirals Not Associated With Increased HCC Recurrence
September 16th 2017Direct acting antivirals, a novel, oral hepatitis C therapy, is associated with a high response rate. DAAs are used in most patients being treated for hepatitis C, including those with decompensated cirrhosis. However, this treatment has been replaced by interferon-based therapy for patients with hepatitis C.
Read More
Improved Responses Found With BLU-554 for Hepatocellular Carcinoma
September 16th 2017According to findings presented at the 11th Annual Conference on the International Liver Cancer Association in Seoul, South Korea, BLU-554 induced an overall response rate of 16% in patients with FGF 19 immunohistochemistry-positive hepatocellular carcinoma. BLU-554 is a potent and highly selective inhibitor of fibroblast growth factor receptor 4.
Read More